Shinobi Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$59M
- Investors
-
10
Shinobi Therapeutics General Information
Description
Developer of cell therapies designed for comprehensive immune evasion. The company is developing a new class of hyperimmune CD8ab iPS-T cells for cancer and other genetic diseases, enabling healthcare industry to use immune therapies to treat diseases.
Contact Information
Website
www.shinobitx.comCorporate Office
- 270 Littlefield Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 270 Littlefield Avenue
- South San Francisco, CA 94080
- United States
Shinobi Therapeutics Timeline
Shinobi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 06-Aug-2024 | $59M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series A) | 01-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | $27.3M | $27.3M | Completed | Startup | ||
| 1. Merger of Equals | 12-Dec-2023 | Completed | Startup |
Shinobi Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series II | ||||||||
| Series I-3 | ||||||||
| Series I-2 | 2,360,059 | $0.000010 | $0.88 | $0.88 | 1x | $0.88 | 2.43% | |
| Series I-1 | 2,124,000 | $0.000010 | $0.81 | $0.81 | 1x | $0.81 | 2.19% |
Shinobi Therapeutics Comparisons
Industry
Financing
Details
Shinobi Therapeutics Competitors (52)
One of Shinobi Therapeutics’s 52 competitors is Mozart Therapeutics, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mozart Therapeutics | Venture Capital-Backed | Seattle, WA | ||||
| iCell Gene Therapeutics | Accelerator/Incubator Backed | Brookhaven, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Synthekine | Venture Capital-Backed | Menlo Park, CA |
Shinobi Therapeutics Patents
Shinobi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025220666-A1 | Cytotoxic lymphocytes expressing variable region-deleted t cell receptors | Pending | 16-Apr-2024 | ||
| EP-4798627-A2 | Sirp alpha engager cells | Pending | 27-Oct-2023 | ||
| AU-2024369017-A1 | Sirpα engager cells | Pending | 27-Oct-2023 | ||
| WO-2025090961-A2 | Sirpα engager cells | Inactive | 27-Oct-2023 | ||
| WO-2025090961-A3 | Sirpα engager cells | Inactive | 27-Oct-2023 | A61K35/17 |
Shinobi Therapeutics Signals
Shinobi Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| D3 (Tokyo) | Venture Capital | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Fast Track Initiative | Venture Capital | Minority |
Shinobi Therapeutics Acquisitions (1)
Shinobi Therapeutics’s most recent deal was a Merger/Acquisition with Thyas. The deal was made on 12-Dec-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Thyas | 12-Dec-2023 | Merger/Acquisition | Biotechnology |
Shinobi Therapeutics FAQs
-
When was Shinobi Therapeutics founded?
Shinobi Therapeutics was founded in 2023.
-
Where is Shinobi Therapeutics headquartered?
Shinobi Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Shinobi Therapeutics?
Shinobi Therapeutics has 40 total employees.
-
What industry is Shinobi Therapeutics in?
Shinobi Therapeutics’s primary industry is Drug Discovery.
-
Is Shinobi Therapeutics a private or public company?
Shinobi Therapeutics is a Private company.
-
What is Shinobi Therapeutics’s current revenue?
The current revenue for Shinobi Therapeutics is .
-
How much funding has Shinobi Therapeutics raised over time?
Shinobi Therapeutics has raised $78.3M.
-
Who are Shinobi Therapeutics’s investors?
Astellas Venture Management, D3 (Tokyo), Eight Roads, EQT Life Sciences, and Fast Track Initiative are 5 of 10 investors who have invested in Shinobi Therapeutics.
-
Who are Shinobi Therapeutics’s competitors?
Mozart Therapeutics, iCell Gene Therapeutics, Neurona Therapeutics, Sangamo Therapeutics, and Synthekine are some of the 52 competitors of Shinobi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process